NCIC CLINICAL TRIALS GROUP

# GYNECOLOGY

## DISEASE SITE COMMITTEE MEETING AGENDA

### DELTA CHELSEA HOTEL, TORONTO, ON

## Room: Churchill В

#### April 30, 2011 – 9:00 A.M. - 3:30 P.M.

CHAIR: GAVIN STUART

(3:30 A.M. – 4:30 P.M. EXECUTIVE COMMITTEE MEETING – CLOSED)

#### CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

#### Learning Objectives:

- To review the results of recent clinical trials in gynecologic oncology and to enhance understandings of the trials' results with respect to intervention adoption.
- To review aspects of standard care of patients with gynecologic cancer specifically as these practices relate to new NCIC CTG priority initiatives (e.g., ovarian cancer [first line therapy; therapy for platin-resistant disease], cervical cancer).
- To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to gynecologic cancers.
- To review QoL outcomes and the implications of adopting trial results (e.g., EN.5) and to discuss QoL methodological issues as these relate to gynecologic cancers.

9:00 a.m.	GYNE COMMITTEE – WELCOME Introduction of guests	G. Stuart/R. Meyer
	Overview of activity, opportunities and the current env	ironment of NCIC CTG clinical trials
9:15 a.m.	IND ACTIVITY	H. Hirte
9:45 a.m.	GYNE COMMITTEE LIAISONS/REPS REPORTS	CRA/Pharm/Lay/Econ./QoL
10:15 a.m.	BREAK	
10:35 a.m.	GYNE CORRELATIVE SCIENCE & TUMOUR BIOLO	
10:50 a.m.	ENDOMETRIUM	A. Mes-Masson
	→ Phase III - EN5 (QoL & SAQ analysis) - EN7/PORTEC 3 - EN8	T. Whelan/D. Tu/H. Lukka P. Bessette/A. Fyles R. Meyer
	$\rightarrow$ IND Studies - IND.192 (deforolimus)	H. Hirte/E. Eisenhauer

11:15 a.m.	$\begin{array}{c} \hline \textbf{CERVIX} \\ \rightarrow & PHASEIII \\ & -NCICCTGCX.5/GCIG \\ & -CXC1//GOG0219 \\ & -OUTBACK-update \\ \hline \\ \rightarrow & INDStudies - IND199 \ (temsirolimus) \end{array}$	SHAPE Study T. Fyles P.Craighead P. Craighead H.Mackay
11:40 a.m.	NCI US GCSC UPDATE	G. Stuart
11:50 a.m.	GCIG UPDATE	G. Stuart
12:00 p.m	LUNCH	
1:30 p.m.	<ul> <li>OV/XL 184</li> <li>Symptom Benefit Pilot update (ANZGOC</li> <li>Malignant Bowel Obstruction study</li> </ul>	H. Mackay/D. Provencher/L. Tinker M.Carey H.Hirte GStuart(for Heywood)/RMeyer(for Brundage) H. Hirte/A. Tinker/E. Eisenhauer G) L. Elit J. Dodge(for Oza)
3:15 p.m.	Q & A/DISCUSSIONS	

- 3:30 p.m. <u>ADJOURN</u>
- 3:30 p.m. GYNE EXECUTIVE CLOSED MEETING